Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Fungal Keratitis Treatment Market

Fungal Keratitis Treatment Market Size

  • Report ID: GMI9024
  • Published Date: Apr 2024
  • Report Format: PDF

Fungal Keratitis Treatment Market Size

Fungal Keratitis Treatment Market was valued at USD 875.4 million in 2023 and is anticipated to experience growth at a CAGR of 6.1% from 2024 to 2032 driven by increasing incidence of eye infections and growing geriatric population.

 

For instance, according to the World Health Organization, by 2031, 1 in 6 people will be aged 60 years and above all over the globe. With the global population aging rapidly, particularly in developed countries, there is a parallel increase in the prevalence of age-related eye conditions, including fungal keratitis. Thus, this demographic trend significantly drives the demand for fungal keratitis treatment. Furthermore, advances in research and development activities contribute to the discovery of novel antifungal drugs, drug delivery systems, diagnostic tools, and therapeutic approaches for fungal keratitis treatment, thereby propelling the growth of this market.
 

Fungal keratitis is a serious eye infection caused by various types of fungi. It typically occurs when fungi invade the cornea, the clear dome-shaped surface that covers the front of the eye. Fungal keratitis can result from injury to the eye, prolonged use of contact lenses, or from fungal spores present in the environment. Fungal keratitis treatment refers to the management and therapeutic interventions employed to address fungal keratitis. It involves various approaches aimed at eliminating the fungal infection, reducing inflammation, and promoting healing of the affected cornea.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global fungal keratitis treatment market was valued at USD 875.4 million in 2023 and is anticipated to grow at 6.1% CAGR from 2024 – 2032, attributed to increasing incidence of eye infections and growing geriatric population.

The geriatric segment in the fungal keratitis treatment industry is anticipated to reach USD 711.2 million by 2032, due to age-related changes in the immune system, ocular surface, and underlying medical conditions such as diabetes and immunosuppression.

North America fugal keratitis treatment market was valued at USD 353.7 million in 2023 and is anticipated to reach USD 585.6 million by 2032, owing to advanced healthcare infrastructure, high prevalence of risk factors and stringent regulatory framework.

Alvogen , Aurolab , Bausch Health Companies Inc., Eyevance Pharmaceuticals LLC , Gilead Biosciences, Inc. , Glenmark Pharmaceuticals Ltd., Leadiant Biosciences, Inc., Merck & Co. Inc., Novo Holdings A/S (Xellia Pharmaceuticals) and Pfizer Inc.

Fungal Keratitis Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 622
  • Countries covered: 22
  • Pages: 362
 Download Free Sample